Skip to main content
TipRanks
Go Ultimate75% OFF

Arbutus Biopharma (I9DN) Q3 2024 Earnings Report

1 Followers

DE:I9DN Q3 2024 EPS Results

Actual EPS
-EUR 0.09
Consensus EPS
-EUR 0.08
Beat/Miss
Missed by -EUR 0.01
One Year Ago EPS
-EUR 0.11

DE:I9DN Q3 2024 Revenue Results

Actual Revenue
EUR 1.20M
Expected Revenue
EUR 1.67M
Beat/Miss
Missed by -EUR 466.48K
YoY Revenue Growth
-71.25%

Earnings Announcement Details

Quarter
Q3 2024
Date
11/06/2024
Time
Before Open
Conference Call
Wednesday, November 6, 2024
DE:I9DN Upcoming Earnings

Arbutus Biopharma's next earnings date is estimated for March 4, 2027, based on past reporting schedules.

Q3 2024 Earnings Call Audio

DE:I9DN Q3 2024 Earnings Call
0:00 / 0:00

Q3 2024 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2024 Earnings Call Summary

Q3 2024
Earnings Call Date:Nov 06, 2024|% Change Since:4.70%|
Earnings Call Sentiment|Positive

The earnings call reflects a positive outlook with strong financial positioning and promising clinical trial data for HBV treatments. However, ongoing legal challenges and high operational cash burn present concerns.

Company Guidance

In the third quarter 2024 earnings call for Arbutus Biopharma, the company provided several key metrics and updates on their ongoing efforts to develop a functional cure for chronic hepatitis B (HBV). They reported having approximately $131 million in cash and investments, with a projected cash burn for 2024 between $63 million and $67 million, ensuring their financial runway extends into the fourth quarter of 2026. The company is advancing their RNAi therapeutic imdusiran through Phase IIa trials, IM-PROVE I and II, which have shown promising results, such as a 33% surface antigen loss in Cohort A1 and 67% in patients with baseline antigen levels below 1,000 IU/mL. Moreover, they are progressing with their AB-101 clinical trial, with evidence of dose-dependent receptor occupancy in Phase Ia/Ib, and anticipate reporting preliminary HBV patient data in the first half of next year. The litigation with Moderna and Pfizer/BioNTech is ongoing, with a trial date set for September 2025 and a Markman hearing on December 18, 2024.

  • Strong Financial PositionArbutus ended Q3 2024 with $131 million in cash, sufficient to fund operations into Q4 2026. A $44 million net proceeds from common shares issuance offset $54.5 million in operational cash usage.
  • Promising Clinical Data for Hepatitis B TreatmentImdusiran showed promising results in reducing surface antigen levels in HBV patients. In Cohort A1 of the IM-PROVE I trial, 33% of patients achieved surface antigen loss sustained at 24 weeks post-treatment, with 67% of those with baseline less than 1,000 IU/mL maintaining loss.
  • Upcoming Data PresentationsUpcoming presentations at the Liver Meeting 2024 and AASLD will showcase additional data from ongoing HBV trials, indicating continued progress and interest in Arbutus' research.

DE:I9DN Earnings History

DE:I9DN earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 04, 20272026 (Q4)-0.02--0.01――
Nov 10, 20262026 (Q3)-0.020.27-0.04850.00% (+0.30)
Aug 12, 20262026 (Q2)-0.02-0.030.01-400.00% (-0.04)
May 13, 20262026 (Q1)-0.030.78-0.12769.23% (+0.90)
Mar 23, 20262025 (Q4)-0.03-0.01-0.0685.71% (+0.05)
Nov 13, 20252025 (Q3)-0.03-0.04-0.0960.00% (+0.05)
Aug 06, 20252025 (Q2)-0.040.01-0.1109.09% (+0.11)
May 14, 20252025 (Q1)-0.09-0.12-0.09-30.00% (-0.03)
Mar 27, 20252024 (Q4)-0.07-0.06-0.1141.67% (+0.04)
Nov 06, 20242024 (Q3)-0.08-0.09-0.1116.67% (+0.02)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed